- CEO
- Ya Qi Dou
- Full Time Employees
- 4,832
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 220-1, Baiyun Avenue Guiyang GZ China 550008
- IPO Date
- Mar 8, 2004
- Business
- Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SS) researches, develops, produces and sells pharmaceutical products principally in China; the company engages in pharmaceutical industry, medical services and big health industry segments. It manufactures chemical drugs, traditional Chinese medicines and biological drugs in forms including capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills and oral solutions targeting tumor, cerebrovascular, respiratory, rheumatism, digestive, pediatric, gynecological, anti-infection, anti-inflammatory and analgesic therapeutic areas; key products encompass injectable loboplatin (10mg and 50mg), Aidi injection, ginkgo damole injection, compound cantharide capsules, Ximaitong capsules, Rikitong blood drop pills, Dandeng Yiyang capsules, gynecologic hemostatic granules, gynecologic menstrual relief pills, Ishirokang tablets, Jinlian purifying effervescent tablets and Keke family cough products. Medical services involve operation and management of comprehensive hospitals, tumor specialty hospitals and tumor radiotherapy centers such as Mianyang Fulian Hospital, Liaoyang Zhongao Hospital and Deyang Cancer Hospital; big health offerings feature Miao medicine-based products including candy, plant beverages and ointments. Founded in 1995 and headquartered at No. 220-1 Baiyun Avenue, Yunyan District, Guiyang, Guizhou, the company listed on the Shanghai Stock Exchange in 2004 as Guizhou's first private listed enterprise and employs around 5,260 people with domestic market focus. In August 2025, it announced acquisition of Guizhou Yibai Traditional Chinese Medicine Formula Granule Pharmaceutical Co Ltd for CNY 11.15 million to expand traditional Chinese medicine capabilities; recent developments include resumption of production and sales for pediatric cough syrups following regulatory notices and integration of AI models like DeepSeek for administrative, medical and GMP compliance applications.